EGFR and breast adenocarcinoma: In the comparison of two different dual selective “targeted” delivery strategies, the combination of gemcitabine-(C4-amide)-[anti-EGFR] with epirubicin-(C3-amide)-[anti-HER2/neu] consistently displayed a trend for exerting greater selectively “targeted” anti-neoplastic cytotoxicity against chemotherapeutic-resistant mammary adenocarcinoma than did gemcitabine-(C4-amide)-[anti-EGFR] with gemcitabine-(C4-amide)-[anti-HER2/neu] at and between the chemotherapeutic-equivalent concentrations of 10−9 M and 10−6 M (Figure.